A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study When Metformin Hydrochloride 500 mg is Added on to SYR-322 25 mg in Type 2 Diabetic Patients
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Alogliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 28 Sep 2015 Primary endpoint (HbA1c) has been met, according to a Takeda media release.
- 31 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.